Canadian radioisotope developer MDS Nordion, a division of Toronto-based MDS, reported no increase in revenues for its fiscal 2006 third quarter (end-July 31).
For the period, revenue was $74 million Canadian ($66.7 million U.S.), compared with $74 million ($66.7 million) in the same period last year.
However, the Kanata, Ontario-based firm reported that adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) were $17 million ($15.3 million), a 23% downturn from the $22 million ($19.8 million) in adjusted EBITDA reported for the fiscal 2005 third quarter.
By AuntMinnie.com staff writers
September 7, 2006
Related Reading
MDS Nordion Q2 shows gains, June 8, 2006
MDS Nordion moves closer to end users, June 7, 2006
MDS Nordion, Molecular Insight Pharmaceuticals partner, February 16, 2006
MDS Nordion collaborates with GSK, November 27, 2005
MDS Nordion to supply yttrium-90 to Berlex, September 20, 2005
Copyright © 2006 AuntMinnie.com
